The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
BUSINESS
Otsuka Taps Autoimmune Diseases as Strategic Pillar for Long-Term Growth
Otsuka Holdings has declared autoimmune diseases as a new strategic focus area, aiming to develop the therapeutic field into a next-generation growth driver, President and CEO Makoto Inoue said on an online business strategy briefing on July 16. “We plan…
To read the full story
Related Article
- Otsuka Bags Autoimmune Antibody Drug from Swedish Biotech
July 16, 2025
- Otsuka Bags Rights to Bispecific T-Cell Engager from China’s Harbour
June 24, 2025
- Otsuka Picks Up Jnana Therapeutics for US$800 Million
August 2, 2024
- Otsuka Ventures into Antibody Space with Visterra Buyout
July 12, 2018
BUSINESS
- Bayer/Santen to Launch Eylea Bio-AG on February 2
January 9, 2026
- Nxera Bags Japan, Select APAC Rights to Santhera’s DMD Therapy
January 9, 2026
- Keio Offshoot Taps Alfresa Know-How for Cell Therapy Push, Bets on Dual iPS Strategy
January 9, 2026
- Asahi Kasei Sees Tarpeyo Uptake Outpacing Forecast, Peak Sales Can Be Higher
January 9, 2026
- Rakuten Ramps Up Photoimmunotherapy PIII with Financing, Eyes US Filing in 2028
January 9, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…